glp-1 inflammation and Gut Health: Addressing Metabolic Dysfunction for Physicians GLP-1 Receptor Agonists as Emerging

The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements

Information and statements about products and health conditions have not been evaluated by the Food and Drugs Administration (FDA), nor has the FDA approved the products to diagnose, cure or prevent disease

However, these side effects are often intermittent, mild, and short-lived, Fishman says

Inoue, K

In athymic mice, tumor size decreased after exendin4 treatment to almost half the size of the tumors of the control

10.1111/dom.13761 Summary Keywords anti-inflammatory, atherosclerosis, coronary artery disease, glucagon-like peptide-1, mechanisms Citation Skrobucha A, Pindlowski P, Krajewska N, Grabowski M and Jonik S (2024) Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review